GlassScriptPhysician profile
Reza Gamagami
NPI 1275517153
$1,186,408.37
in general payments reported to CMS, 2019-2025
39 companies · $118K in 2025
The $118K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183K · 2020: $191K · 2021: $198K · 2022: $142K · 2023: $156K · 2024: $199K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $342K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Travel and Lodging: $40K · Consulting Fee: $13K · Food and Beverage: $7,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $342,094.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,250.00 |
| Travel and Lodging | $40,101.68 |
| Consulting Fee | $12,750.00 |
| Food and Beverage | $7,714.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,158,832.79 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| W. L. Gore & Associates, INC. | $12,425.15 | 2019-2023 | Gore Synecor Biomaterial |
| Davol INC. | $6,416.05 | 2019-2025 | Phasix Mesh, Bard 3dmax Mesh |
| Covidien LP | $2,360.70 | 2019 | |
| Baxter Healthcare | $2,130.45 | 2019-2024 | Tisseel |
| Cook Medical LLC | $1,000.00 | 2019 | |
| Ethicon US, LLC | $583.61 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $386.14 | 2021-2023 | |
| Abbvie INC. | $326.46 | 2020-2025 | |
| Medtronic, INC. | $248.17 | 2021-2024 | Progrip, Endoflip, Gi Genius |
| Merck Sharp & Dohme LLC | $186.81 | 2023-2024 | Bridion |
| Becton, Dickinson and Company | $181.33 | 2023-2024 | Phasix Mesh |
| Braintree Laboratories, INC. | $164.54 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $150.71 | 2024 | |
| Endogastric Solutions, INC | $148.43 | 2021-2023 | Esophyx |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $123.27 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kci USA, INC. | $72.90 | 2019 | |
| Histosonics, INC. | $68.55 | 2024 | |
| Conmed Corporation | $56.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.29 | 2023 | Gattex |
| Smith+Nephew, INC. | $49.98 | 2019-2024 | Stravix |
| Vertex Pharmaceuticals Incorporated | $48.16 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $47.62 | 2020-2022 | |
| Integra Lifesciences Corporation | $45.27 | 2019-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Heron Therapeutics, INC. | $45.00 | 2023 | Zynrelef |
| Ambu INC. | $32.74 | 2022 | |
| Dilon Technologies, INC. | $29.02 | 2023 | Hemoblast Bellows |
| Qol Medical, LLC | $24.68 | 2024 | Sucraid |
| Innocoll Pharmaceuticals Limited | $24.27 | 2022 | |
| Polynovo North America LLC | $23.89 | 2022 | |
| Sirius Medical Systems | $21.90 | 2024 | Pintuition |
| Coopersurgical, INC. | $16.73 | 2025 | Onetrac Lx |
| Medtronic USA, INC. | $16.43 | 2020 | |
| Baudax Bio INC. | $15.39 | 2021 | |
| Exact Sciences Corporation | $14.87 | 2023 | Cologuard Collection Kit |
| Osiris Therapeutics INC. | $13.86 | 2019 | |
| Tei Biosciences INC | $12.72 | 2019 | |
| Monaghan Medical Corporation | $11.22 | 2023 | Aerobika |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Gamagami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.